327 results on '"Gatto Lidia"'
Search Results
2. Machine learning in neuro-oncology: toward novel development fields
3. Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?
4. Economic income and survival in patients affected by glioblastoma: A systematic review and meta-analysis.
5. Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis
6. Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?
7. Economic income and survival in patients affected by glioblastoma: A systematic review and meta-analysis
8. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
9. The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
10. Toward a genome-based treatment landscape for renal cell carcinoma
11. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes
12. Immune-checkpoint inhibitors in pituitary malignancies
13. Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials
14. Olfactory neuroblastoma: diagnosis, management, and current treatment options
15. Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis
16. A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss
17. An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor
18. Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
19. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy
20. DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open
21. CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap
22. Letter concerning “Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between ORR and median overall survival”: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma
23. The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
24. Data from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
25. Revised supplementary Figure 1 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
26. Revised supplementary Figure 2 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
27. Revised supplementary Table 1 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
28. Revised supplementary Table 4 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
29. Revised supplementary Table 2 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
30. Revised supplementary Table 3 from Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST
31. Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab?
32. Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib
33. Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
34. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
35. How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments
36. Beyond Imaging and Genetic Signature in Glioblastoma: Radiogenomic Holistic Approach in Neuro-Oncology
37. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure
38. Adult Medulloblastoma: Updates on Current Management and Future Perspectives
39. Tumor-Associated Microenvironment of Adult Gliomas: A Review
40. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
41. Adult Medulloblastoma: Updates on Current Management and Future Perspectives
42. Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance
43. BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma
44. Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?
45. Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis
46. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem
47. PATH-15. NON-CANONICAL IDH 1 AND IDH 2 MUTATIONS ARE ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH GLIOMAS: RESULTS OF A META-ANALYSIS
48. How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments.
49. Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets
50. Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.